Back to news

Medicure Reports Financial Results for Quarter Ended September 30, 2026 and Schedules November 23, 2026 Conference Call

ACCESSWIRE•19/11/2026•16:00 ET
0

Key Highlights

  • ➤Q3 net revenue $7.9 million, down from $8.2 million year over year
  • ➤Q3 adjusted EBITDA loss widened to $820,000 from $597,000
  • ➤Q3 net loss $1.3 million, or $0.13 per share
  • ➤Cash fell to $1.1 million from $3.8 million at December 31, 2025
  • ➤AGGRASTAT revenue declined to $979,000 amid generic tirofiban competition

Expert Statements

Albert D. Friesen, Chief Executive Officer of Medicure

“Medicure invested $676,000 in research and development during the quarter ended September 30, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of the Company's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders;”

WINNIPEG, MB / ACCESS Newswire / November 19, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2026 and will have a conference call to present the Financial Results on November 23, 2026 at 8:30 am Eastern Time.

Quarter Ended September 30, 2026 Highlights: * Recorded total net revenue of $7.9 million during the period ended September 30, 2026, compared to $8.2 million for the period ended September 30, 2025; * Recorded total net revenue from the sale of ZYPITAMAG(®)of $1.7 million ($781,000 through the traditional insured channels, and $930,000 through Marley Drug) during the quarter ended September 30, 2026, compared to $1.7 million ($769,000 through the traditional insured channels, and $917,000 through Marley Drug) for the quarter ended September 30, 2025; * Recorded total net revenue from the sale of AGGRASTAT(®) of $979,000 during the quarter ended September 30, 2026, compared to $1.0 million during the quarter ended September 30, 2025; * The Pharmacy Business Segment, which includes Marley Drug, and the Company's two 2025 acquired pharmacies, Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $6.1 million ($930,000 from sales of ZYPITAMAG(®), and $5.2 million from other pharmacy revenue) during the quarter ended September 30, 2026, compared to net revenue of $6.4 million ($917,000 from sales of ZYPITAMAG(®), and $5.4 million from other pharmacy revenue) during the quarter ended September 30, 2025; * Medicure invested $676,000 in research and development during the quarter ended September 30, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of the Company's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders; * Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA(1)) for the quarter ended September 30, 2026 was negative $820,000, compared to negative adjusted EBITDA of $597,000 for the quarter ended September 30, 2025 and; * Net loss for the quarter ended September 30, 2026 was $1.3 million or $0.13 per share, compared to a net loss of $1.4 million or $0.13 per share for the quarter ended September 30, 2025; the net loss includes non-cash expenses of $669,000 relating to amortization of the assets relating to the purchase of ZYPITAMAG(®) and the Pharmacy Business Segment. Financial Results

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in